Cochlear Ltd
ASX:COH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
275.61
350.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Cochlear Ltd
Cochlear Ltd
Cash & Cash Equivalents
Cochlear Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$513.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
46%
|
CAGR 10-Years
25%
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
Cash & Cash Equivalents
AU$762.9k
|
CAGR 3-Years
-54%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-21%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Cash & Cash Equivalents
AU$24.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash & Cash Equivalents
AU$27.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
37%
|
CAGR 10-Years
35%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$6.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
28%
|
CAGR 10-Years
56%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$18.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
Glance View
Cochlear Ltd., the renowned medical device company, traces its roots back to the vibrant medical innovation scene of Australia in the 1980s. Born from the pioneering research of Professor Graeme Clark, who was driven by a personal mission to help the hearing-impaired, Cochlear embarked on a journey that redefined the possibilities for those living with hearing loss. Over the years, the company has evolved into a global leader in implantable hearing solutions, headlined by its flagship cochlear implants. These intricate devices bypass damaged portions of the ear, directly stimulating the auditory nerve to restore the sense of hearing, thus providing users with the ability to connect more profoundly with the world around them. As scientific research advanced, so did Cochlear, developing a range of complementary products tailored to different degrees and types of hearing impairment. In a business model built on innovation and patient support, Cochlear generates revenue by designing, manufacturing, and marketing a portfolio of hearing implant products and related services. The company's value proposition lies not only in the initial sale of these high-tech devices but also in the ongoing customer relationships through upgrades, accessories, and maintenance services. By investing significantly in research and development, Cochlear ensures continuous improvement and the introduction of new solutions that meet the evolving needs of patients and healthcare providers. Their ability to offer comprehensive post-implantation support, such as rehabilitation services and patient care programs, strengthens customer loyalty and establishes recurring revenue streams, enabling Cochlear to maintain its competitive edge in the global market.
See Also
What is Cochlear Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
513.6m
AUD
Based on the financial report for Jun 30, 2024, Cochlear Ltd's Cash & Cash Equivalents amounts to 513.6m AUD.
What is Cochlear Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
25%
Over the last year, the Cash & Cash Equivalents growth was -8%. The average annual Cash & Cash Equivalents growth rates for Cochlear Ltd have been -6% over the past three years , 46% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet